Pharmafile Logo

Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access

May 5, 2026 | Pharma, healthcare, patient access 

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

- PMLiVE

Inizio announced the official launch of its fully integrated, end-to-end Hub Services, a cornerstone of its market-leading Patient Solutions offering. Delivered by Inizio Engage, the Inizio business unit specializing in patient engagement and support, this next-generation solution addresses the growing complexity of patient access, reimbursement, and adherence, while enabling clients to partner with a more agile, strategic, and outcome-driven organization.

As life sciences organizations navigate an increasingly dynamic policy and payer landscape, and higher expectations from patients, the need for more connected, patient-centric support models has never been greater. “Inizio Engage’s evolved Hub Services introduces a next-generation approach, integrating human expertise, intelligent technology, and pharmacy capabilities, supported by advanced analytics to simplify and accelerate the path to therapy,” said Ryan Quigley, CEO, Inizio. “This launch represents another opportunity for Inizio to lead the way as the global Intelligent Commercialization partner, bringing together insight, innovation, and execution to deliver more coordinated, patient-centered solutions for our clients.”

Read full article here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Healthcare in the age of AI: How will artificial intelligence impact future decision-making?

Authored by: Constanza Salas, Jhon Galindo and Rachel Howard

Therapy Watch launches new tracker covering Postpartum Depression

The new Therapy Watch Postpartum depression (PPD) study is the first tracker in the series to cover Psychiatry

Infographic: Rare Diseases in China

How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.

Man vs microbe: the fight against antimicrobial resistance

How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.

Research Partnership Senior Director Andrew Stokes appointed new role as Chief Commercial Officer

With over 20 years’ experience in the industry, Research Partnership Senior Director and market research veteran Andrew Stokes has been appointed Chief Commercial Officer.

Case study: How we enhanced the power of a global ATU using our advanced analytics solution, Equity AI

Find out how we provided a more holistic understanding of brand equity and a forward indication of potential market share using our advanced analytics solution, Equity AI.

Article: Creating truly effective communications – the impact of high speed, high octane messaging

In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.

Research Partnership makes two senior appointments to bolster its US and MedTech operations

Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.